Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs

Zhang, Chengjuan; Wei, Bing; Li, Peng; Yang, Ke; Wang, Zhizhong; Ma, Jie; Guo, Yongjun

doi:10.1371/journal.pone.0173524

Cited by 12 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wei B[ 21 ] implicated that tumor genesis driven by different EGFR mutations were mechanistically different. Zhang C[ 22 ] showed that patients with mutation of T790M had poor prognosis. As we all know, PFS and OS for advanced NSCLC patients with an exon 19 mutation was considerably higher than those with other subtypes of EGFR mutations[ 23 , 24 ].…”

Section: Discussionmentioning

confidence: 99%

Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma

et al. 2018

Self Cite

View full text Add to dashboard Cite

AimsIn this study, we determined whether different subtypes of epidermal growth factor receptor (EGFR) exon19 mutation are associated with the therapeutic effect of EGFR-tyrosine kinase inhibitors (TKIs) on advanced non-small cell lung adenocarcinoma.MethodsA total of 122 patients with stage III or IV non-small cell lung adenocarcinoma were retrospectively reviewed. Clinical characteristics of these patients, including progression-free survival (PFS) outcome for EGFR-TKI treatment, were analyzed.ResultsAccording to the mutation pattern, we classified the in-frame deletions detected on EGFR Exon19 into three different types: codon deletion (CD), with a deletion of one or more original codons; codon substitution and skipping (CSS), with a deletion of one or two nucleotides but the residues could be translated into a new amino acid without changing following amino acid sequence; CD or CSS plus single nucleotide variant (SNV) (CD/CSS+SNV), exclude CD or CSS, there’s another SNV nearby the deletion region. The clinical characteristics of three groups were analyzed and as a result, no significant difference was found. By comparing the average number of missing bases and amino acids of the three mutation subtypes, it could be discovered that the number of missing bases and amino acids of the three mutation subtypes is diverse, and group CSS> group CD> group CD/CSS+SNV. Finally, survival analysis was performed between three groups of patients. The median PFS of group CD, group CSS and group CD/CSS+SNV was 11 months, 9 months and 14 months respectively. There was a distinct difference in the PFS between group CSS and group CD/CSS+SNV (P = 0.035<0.05), and the PFS of group CD/CSS+SNV was longer.ConclusionsDifferent mutation subtypes of EGFR exon19 can predict the therapeutic effect of EGFR-TKIs on advanced non-small cell lung adenocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Whereas, the maintained positive status of EGFR mutation in plasma after treatment with EGFR TKI is also the worse factor for survival [13–15, 28, 29]. In the same way, the role of secondary plasma-T790M mutation in prognosis for NSCLC patients also was mentioned in previous studies with opposite opinions [9, 14, 15, 17, 19]. While the studies of Sueo-Aragane et al [14], Zheng et al [15], and Zhang et al [17] shown that the occurrence of T790M in plasma after TKI treatment is the worse prognostic factor for OS and PFS, Sakai et al [9] only noted this prognostic role of T790M in the patient group under 65 years old.…”

Section: Introductionmentioning

confidence: 91%

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non‐small cell lung cancer

Phan

Tran

Nguyen

et al. 2019

Clinical & Translational Med

View full text Add to dashboard Cite

Background This study aims to clarify the prognostic role of epidermal growth factor receptor ( EGFR ) mutations in plasma of non-small cell lung cancer (NSCLC) for resistance to tyrosine kinase inhibitor (TKI), in correlation with clinical characteristics. A total of 94 Adenocarcinoma, clinical stage IV NSCLC patients with either E19del or L858R mutation were admitted to the prospective study from Jan-2016 to Jul-2018. EGFR mutations in plasma were detected by scorpions ARMS method. The Kaplan–Meier and Cox regression methods were used to estimate and test the difference of progression-free survival (PFS) and overall survival (OS) between groups. The prognostic power of each factor was appraised by the Bayesian Model Averaging (BMA) method. Results Among 94 patients, 28 cases still are good responses according to the RECIST criteria and negative for EGFR mutations in plasma. Of 66 resistant patients, EGFR mutations were positive in plasma of 57 cases (86.4%) which was higher than the value of pre-treatment (48.5%). Of which, 17 patients (25.8%) have the occurrence of EGFR mutations in plasma earlier than progression 2.1 (0.6–7.9) months. The secondary T790M mutation was found in the plasma of 32 cases (48.5%). Median PFS and OS for the study subjects were 12.9 (11.0–14.2) and 29.5 (25.2–41.3) months, respectively. The post-treatment EGFR plasma test with brain and new metastasis were detected as independent prognostic factors for worse PFS ( P = 0.008, 0.016 and 0.028, respectively). While EGFR plasma ( P = 0.044) with bone metastasis at baseline ( P = 0.012), new metastasis ( P = 0.003), and high cfDNA concentration ( P = 0.004) serve as the worse survival factors, surgery treatment helps to prolong OS in NSCLC treated with EGFR TKI ( P = 0.012). BMA analysis identified EGFR plasma test as the strongest prognostic factor for both PFS and OS (possibility of 100% and 99.7%, respectively). Conclusions EGFR plasma test is the powerfully prognostic factor for early resistance with EGFR TKI and worse survival in NSCLC regardless of clinical characteristics.

show abstract

“…Wei B [20] implicated that tumor genesis driven by different EGFR mutations were mechanistically different. Zhang C [21] showed that patients with mutation of T790M had poor prognosis. As we all know, PFS and OS for advanced NSCLC patients with an exon 19 mutation was considerably higher than those with other subtypes of EGFR mutations [22,23].…”

Section: Discussionmentioning

confidence: 99%

Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma

Tian

Zhao

Ren

et al. 2018

Preprint

Self Cite

View full text Add to dashboard Cite

AimsIn this study, we determined whether different subtypes of epidermal growth factor receptor (EGFR) exon19 mutation are associated with the therapeutic effect of EGFR-tyrosine kinase inhibitors (TKIs) on advanced non-small cell lung adenocarcinoma. MethodsA total of 122 patients with stage III or IV non-small cell lung adenocarcinoma were retrospectively reviewed. Clinical characteristics of these patients, including progression-free survival (PFS) outcome for EGFR-TKI treatment, were analyzed. ResultsAccording to the mutation pattern, we classified the in-frame deletions detected on EGFR Exon19 into three different types: codon deletion (CD), with a deletion of one or more original codons; codon substitution and skipping (CSS), with a deletion of one or two nucleotides but the residues could be translated into a new amino acid without changing following amino acid sequence; CD or CSS plus single nucleotide variant (SNV) (CD/CSS+SNV), exclude CD or CSS, there's another SNV nearby the deletion region. The clinical characteristics of three groups were analyzed and as a result, no significant difference was found. By comparing the average number of missing bases and amino acids of the three mutation subtypes, it could be discovered that the number of missing bases and amino acids of the three mutation subtypes is diverse, and group CSS> group CD> group CD/CSS+SNV. Finally, survival analysis was performed between three groups of patients. The median PFS of group CD, group CSS and group CD/CSS+SNV was 11 months, 9 months and 14 months respectively.There was a distinct difference in the PFS between group CSS and group CD/CSS+SNV (P=0.035<0.05), and the PFS of group CD/CSS+SNV was longer. ConclusionsDifferent mutation subtypes of EGFR exon19 can predict the therapeutic effect of EGFR-TKIs on advanced non-small cell lung adenocarcinoma.

show abstract

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs

Cited by 12 publications

References 33 publications

Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma

Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non‐small cell lung cancer

Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma

Contact Info

Product

Resources

About